Biocytogen and IDEAYA Biosciences push IDE034 into the clinic as dual-antigen ADC strategies mature
IDEAYA Biosciences doses first patient in IDE034 Phase 1 trial. Discover what this bispecific ADC means for solid tumor therapy.
IDEAYA Biosciences doses first patient in IDE034 Phase 1 trial. Discover what this bispecific ADC means for solid tumor therapy.